MA30670B1 - Vaccins contre le paludisme - Google Patents

Vaccins contre le paludisme

Info

Publication number
MA30670B1
MA30670B1 MA31671A MA31671A MA30670B1 MA 30670 B1 MA30670 B1 MA 30670B1 MA 31671 A MA31671 A MA 31671A MA 31671 A MA31671 A MA 31671A MA 30670 B1 MA30670 B1 MA 30670B1
Authority
MA
Morocco
Prior art keywords
protein
vivax
derived
relates
fusion
Prior art date
Application number
MA31671A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Christian F Ockenhouse
Anjali Yadava
Original Assignee
Glaxosmithkline Biolog Sa
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Army filed Critical Glaxosmithkline Biolog Sa
Publication of MA30670B1 publication Critical patent/MA30670B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une protéine hybride/de fusion innovante, dérivée de la protéine CS de Plasmodium vivax (P. vivax), des procédés de préparation et de purification de celle-ci, son utilisation en médecine, en particulier pour la prévention des infections paludéennes, par exemple celles causées par P. vivax, des compositions/vaccins contenant la protéine ou des anticorps contre la protéine tels que des anticorps monoclonaux ou polyclonaux et leur utilisation, en particulier dans des buts thérapeutiques. L'invention concerne également des particules lipoprotéiques de ladite protéine hybride et des formulations/vaccins la comprenant et leur utilisation. L'invention concerne en particulier une protéine de fusion hybride immunogène qui comprend: (a) au moins une unité répétitive dérivée de la région répétitive d'une protéine circumsporozoïte de type I de P. vivax, (b) au moins une unité répétitive dérivée de la région répétitive d'une protéine circumsporozoïte de type II de P. vivax, et un antigène de surface S dérivé du virus de l'hépatite B, ou un fragment de celui-ci.
MA31671A 2006-07-18 2009-02-27 Vaccins contre le paludisme MA30670B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
MA30670B1 true MA30670B1 (fr) 2009-08-03

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
MA31672A MA30671B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme
MA31671A MA30670B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA31672A MA30671B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Country Status (22)

Country Link
US (2) US9364525B2 (fr)
EP (2) EP2040743B1 (fr)
JP (2) JP5592110B2 (fr)
KR (2) KR20090094213A (fr)
AR (1) AR061894A1 (fr)
AU (2) AU2007276217B2 (fr)
BR (2) BRPI0714326A2 (fr)
CA (2) CA2657353A1 (fr)
CO (2) CO6150187A2 (fr)
CR (2) CR10555A (fr)
EA (2) EA200900032A1 (fr)
ES (2) ES2525732T3 (fr)
IL (2) IL196410A0 (fr)
MA (2) MA30671B1 (fr)
MX (2) MX2009000655A (fr)
NO (2) NO20090178L (fr)
NZ (2) NZ574239A (fr)
PE (1) PE20080428A1 (fr)
SG (2) SG173363A1 (fr)
TW (1) TW200819462A (fr)
WO (2) WO2008009650A2 (fr)
ZA (1) ZA200900386B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2466431C (fr) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes
SG173363A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
AU2008333208A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccine
AR069936A1 (es) * 2007-12-24 2010-03-03 Glaxosmithkline Biolog Sa Vacunas contra la malaria que comprenden una proteina de fusion derivada de proteina cs de plasmodium vivax y un antigeno s de hepatitis b
BRPI0919245A2 (pt) * 2008-09-24 2021-11-03 Us Gov Sec Army Vacina para malária
BRPI0921651A2 (pt) * 2008-11-03 2015-08-18 Crucell Holland Bv Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123412A1 (fr) * 2012-02-17 2013-08-22 Children's Medical Center Corporation Antigènes trap à conformation stabilisée
US9821046B2 (en) 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof
EP3213638A1 (fr) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Analogue de fromage vegan
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
WO2018104313A1 (fr) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Nouveau procédé
EP3559669A4 (fr) * 2016-12-23 2020-11-18 The Walter and Eliza Hall Institute of Medical Research Système, procédé, appareil et test de diagnostic pour plasmodium vivax
DE112020007612T5 (de) 2020-09-16 2023-06-29 Mitsubishi Electric Corporation Scheinwerfereinrichtung

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
ATE118784T1 (de) * 1985-07-12 1995-03-15 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
WO1988009797A1 (fr) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1993010152A1 (fr) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
WO1994021292A1 (fr) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
CN1134173A (zh) * 1993-09-10 1996-10-23 美国国有健康与人类服务部 间日疟原虫和镰状疟原虫红细胞结合蛋白的结合区
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20030133944A1 (en) * 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CZ302062B6 (cs) 1998-06-30 2010-09-22 Om Pharma Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
HU229255B1 (en) 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU1600401A (en) 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (fr) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
US20040241181A1 (en) 2001-06-22 2004-12-02 Ertl Hildeghund C. J. Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
CA2507915C (fr) 2002-12-17 2013-07-02 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
JP4898434B2 (ja) 2003-06-20 2012-03-14 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー Ｂ型肝炎ウィルスの新規の表面タンパク質（ＨＢｓＡｇ）変異体
ES2478625T3 (es) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US20050233435A1 (en) 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP1846023B1 (fr) * 2005-01-18 2013-09-25 Walter Reed Army Institute of Research Proteine circumsporozoite hybride de plasmodium vivax et son vaccin
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
SG173363A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
AR069936A1 (es) * 2007-12-24 2010-03-03 Glaxosmithkline Biolog Sa Vacunas contra la malaria que comprenden una proteina de fusion derivada de proteina cs de plasmodium vivax y un antigeno s de hepatitis b

Also Published As

Publication number Publication date
IL196410A0 (en) 2011-08-01
MX2009000650A (es) 2009-07-02
NO20090178L (no) 2009-02-09
KR20090094213A (ko) 2009-09-04
JP5592110B2 (ja) 2014-09-17
WO2008009652A3 (fr) 2008-05-08
PE20080428A1 (es) 2008-05-15
AU2007276217A8 (en) 2009-02-26
AR061894A1 (es) 2008-10-01
WO2008009650A3 (fr) 2008-04-10
CA2657279A1 (fr) 2008-01-24
AU2007276217B2 (en) 2013-08-29
MA30671B1 (fr) 2009-08-03
EP2040742A2 (fr) 2009-04-01
BRPI0714326A2 (pt) 2013-05-07
NZ574239A (en) 2011-12-22
EP2040743B1 (fr) 2013-10-02
WO2008009652A2 (fr) 2008-01-24
BRPI0715581A2 (pt) 2013-04-24
EP2040743A2 (fr) 2009-04-01
IL196471A0 (en) 2011-08-01
JP2009543846A (ja) 2009-12-10
WO2008009650A2 (fr) 2008-01-24
EP2040742B1 (fr) 2014-10-29
NZ574238A (en) 2012-02-24
SG173363A1 (en) 2011-08-29
ES2437082T3 (es) 2014-01-08
AU2007276219B2 (en) 2013-10-03
CO6150187A2 (es) 2010-04-20
KR20090092752A (ko) 2009-09-01
US20100150998A1 (en) 2010-06-17
AU2007276217A1 (en) 2008-01-24
JP5222289B2 (ja) 2013-06-26
NO20090177L (no) 2009-02-16
US20100062028A1 (en) 2010-03-11
SG173377A1 (en) 2011-08-29
ZA200900386B (en) 2014-03-26
ES2525732T3 (es) 2014-12-29
AU2007276219A1 (en) 2008-01-24
JP2009543569A (ja) 2009-12-10
CA2657353A1 (fr) 2008-01-24
TW200819462A (en) 2008-05-01
MX2009000655A (es) 2009-07-02
CR10561A (es) 2009-04-29
CO6150189A2 (es) 2010-04-20
EA200900033A1 (ru) 2009-12-30
CR10555A (es) 2009-04-29
US9592282B2 (en) 2017-03-14
EA200900032A1 (ru) 2011-02-28
US9364525B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
MA30670B1 (fr) Vaccins contre le paludisme
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
MA27699A1 (fr) Vaccin contre vhc
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA29458B1 (fr) Composition de vaccin
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
EP1450857A4 (fr) Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
MA32030B1 (fr) Vaccins anti-malaria
Radocha et al. Monoclonal antibodies and antibody drug conjugates in multiple myeloma
MA30478B1 (fr) Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.
WO2005028496A3 (fr) Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
Qiao et al. A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
MA27474A1 (fr) Vaccin
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
HK1058948A1 (en) Malria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
MA32003B1 (fr) Vaccin
TW200738264A (en) Synergistic compositions for treating HIV